Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other
urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome. Participants
will receive either 100 mg AQX-1125, 200 mg AQX-1125 or placebo for the first 12 weeks of the
study. After 12 weeks, all participants will receive either 100 mg or 200 mg AQX-1125 for 52
weeks.